Pacira BioSciences to be Acquired by Viatris

Fried Frank is advising Goldman Sachs & Co. LLC as exclusive financial advisor to Pacira BioSciences, Inc., a leader in innovative non-opioid pain therapies, on its agreement to be acquired by Viatris Inc., a global healthcare company, in a transaction representing an aggregate equity value of $1.65 billion. Viatris plans to maximize the long-term value of the Pacira portfolio, comprised of two established, high-margin, patent-protected, in-market US products, EXPAREL® and ZILRETTA®, and expects to expand the products' reach across select markets within its global infrastructure. For more on the transaction, which is expected to close by the end of 2026, read the companies' press release.

This transaction is a continuation of Fried Frank's work advising Goldman Sachs as financial advisor on high-value deals, which includes the firm previously advising Goldman Sachs as financial advisor to Dana Incorporated on its agreement to combine with Eaton's Mobility business and UniFirst on its agreement to be acquired by Cintas.

M&A and private equity partners Philip Richter and Roy Tannenbaum are leading the Fried Frank team, which includes M&A and private equity associate Caitlin Hubbard.

This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm's data policy page for further information.